Drug
LEO 43204 clinical trials
Also written LEO 43204 and Ingenol Disoxate.
- studies test it
- 13
- open now
- 0
- in phase 3
- 5
- first study started
- 2013
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Studies
Open first, then newest update. How each study uses LEO 43204 is read from its arms, and is right about nine times in ten.
Testing it · 13
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-upCompletedPhase 3LEO PharmaNCT02549352Written as LEO43204 gel
- A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or ScalpTerminatedPhase 3LEO PharmaNCT03115476Written as ingenol disoxate gel 0.018%
- Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-upCompletedPhase 3LEO PharmaNCT02549339Written as LEO 43204 gel
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-upCompletedPhase 3LEO PharmaNCT02547363Written as LEO 43204 gel
- Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-upCompletedPhase 3LEO PharmaNCT02547233Written as LEO 43204 gel
- Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, RespectivelyCompletedPhase 2LEO PharmaNCT02305888Written as LEO 43204
- A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic KeratosisCompletedPhase 1/2LEO PharmaNCT01922050Written as LEO 43204 Formulation 1
- Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe AcneCompletedPhase 2LEO PharmaNCT02575950Written as LEO43204
- Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic KeratosisCompletedPhase 1/2LEO PharmaNCT02100813Written as LEO 43204
- Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic KeratosisCompletedPhase 1/2LEO PharmaNCT02120456Written as LEO 43204
- A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 GelCompletedPhase 1LEO PharmaNCT02650505Written as LEO 43204
- Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use ConditionsCompletedPhase 1LEO PharmaNCT02424305Written as LEO 43204 gel 0.018%
- Biological Effects of LEO 43204 in Actinic KeratosisCompletedPhase 1LEO PharmaNCT02600598Written as LEO 43204 Gel, 0.037%